Reboxetine - studies in previous guideline

Characteristics of included studies

Study	Methods	Participants	Interventions	Outcomes	Notes	AC
Andreoli 2002 Y M	Allocation: Random (no details) Duration: 8 weeks (+4-28 day washout). Analysis: ITT	Inpatients and outpatients. N=381. Age: 18-65. Diagnosis: DSM-III-R major depression without psychotic features, HRSD≥22. Baseline HRSD: reboxetine=26.8 +-3.4, fluoxetine=26.9 +-3.6, placebo=27.4 +-3.6.	1. Reboxetine (8mg up to 10mg after 4 weeks) 2.Fluoxetine (20mg up to 40mg after 4 weeks) 3. Placebo	1. Non-responders (patients not achieving ≥50% decrease in HRSD) 2. Non-remitters (patients not achieving HRSD≤10) 3. Leaving the study early 4. Leaving the study early due to side effects 5. Patients reporting side effects	Conducted in 33 centres in 6 countries.	B
Ban1998 Y I	Allocation: Random (no details).Duration: 4 weeks (+7 day wash-out). Analysis: ITT.	Inpatients. N=258. Age: 18-65. Diagnosis: DSM-III-R major depression, HRSD-17≥16. Mean baseline HRSD: reboxetine = 26.89, placebo = 25.43.	1.Reboxetine(4mg->8mg) 2. Desipramine (100mg->200mg on day 7) 3. Placebo	1. Non-responders (patients not achieving ≥50% decrease in HRSD) 2. Leaving the study early due to side effects	Conducted in at 10 centres in 6 countries.	B
Berzewski 1997 Y M	Allocation: Random (no details). Duration: 6 weeks (+4-14 day washout). Analysis: ITT (patients with ≥ 1 assessment post-baseline).	Inpatients and outpatients. N=256. Age: 18-65. Diagnosis: DSM-III-R major depressive episode, HRSD≥22. Mean baseline HRSD: reboxetine - 28.8 +-4.8, imipramine - 28 +-5.2	1. Reboxetine (8mg up to 10mg) 2. Imipramine (150mg up to 200mg)	1. HRSD mean endpoint scores 2. Leaving the study early 3. Non-responders (patients not achieving ≥50% decrease in HRSD) 4. Non-remitters (patients not achieving HRSD≤10) 5. Leaving the study early due to side effects 6. Patients reporting side effects	Conducted in 22 centres in Germany, Belgium and South Africa.	B
Katona 1999 E M	Allocation: Random (no details). Duration:8	Inpatients and outpatients. N=347. Age: 65+. Diagnosis: DSM-III-R major	1 Reboxetine (4mg up to 6mg)	1 HRSD mean endpoint scores 2 Leaving the study early due to side effects	Conducted in 46 centres in 7	B

	weeks (+ up to 28 day washout) Analysis: ITT	depressive disorder (N=218) or dysthymia (N=129) without psychotic features, HRSD-21≥18, MMSE≥22. Mean baseline HRSD: reboxetine =27+-4.9, imipramine - 26.9 +-5.4.	2. Imipramine (75mg up to 100mg)	3. Non-responders (patients not achieving ≥50% decrease in HRSD) 4. Non-remitters (patients not achieving HRSD≤10) 5. Patients reporting side effects	European countries. Extracted data for 218 patients with MDD only.	
Massana 1999 Y M	Allocation: Random (no details). Duration:8 weeks (up to 28 day washout).Analysis: ITT	Inpatients and outpatients. N=168. Age: 18-65. Diagnosis: DSM-III-R acute major depressive episodes not accompanied by psychotic features, HRSD-21≥22. Mean baseline HRSD: reboxetine = 28.6 +-5.3, fluoxetine=27.4 +-4.1.	1. Reboxetine (8mg up to 10mg) 2. Fluoxetine (20mg up to 40mg)	1. HRSD-21 mean endpoint scores 2. Non-responders (patients not achieving ≥50% decrease in HRSD) 3. Non-remitters (patients not achieving HRSD≤10) 4. Leaving the study early 5. Leaving the study early due to side effects 6. Patients reporting side effects	Conducted at 16 centres in four countries.	B
Versiani 2000B Y I	Allocation: Random (no details) Duration: 6 weeks (+ 7-14 day placebo washout) Analysis: ITT	Inpatients. N=56. Age: 18-65. Diagnosis: DSM-III-R major depression, HRSD-21≥20. Mean baseline HRSD: 35.7, placebo = 35.1.	1. Reboxetine (6mg->10mg) 2. Placebo	1. Non-responders (patients not achieving ≥50% decrease in HRSD) 2. Leaving the study early 3. Leaving the study early due to side effects 4. Patients reporting side effects	Conducted in three centres in Canada and Brazil.	B

Characteristics of excluded studies

Study	Reason for exclusion
Farina2002	Not an RCT
Versiani99 Cont Y M	Not an acute phase trial